智通财经网·2025-11-06 12:04Core Viewpoint - BeiGene (688235.SH) has adjusted its revenue forecast for the fiscal year 2025, projecting revenue between RMB 36.2 billion and RMB 38.1 billion, driven by the strong market position of its product, BeiYueZe®, in the U.S. and its ongoing expansion in Europe and other key global markets [1] Revenue Adjustment - The adjusted revenue forecast for 2025 is set between RMB 36.2 billion and RMB 38.1 billion [1] - The increase in revenue is primarily attributed to the leading position of BeiYueZe® in the U.S. market and its continuous expansion in Europe and other significant global markets [1] Expense Adjustment - Research and development expenses, along with sales and management expenses, are projected to be between RMB 29.5 billion and RMB 30.9 billion [1] - The adjustments in expenses are mainly due to prudent investment strategies that promote revenue growth and pipeline expansion, resulting in significant operational efficiency [1]